NASDAQ: SOPH
Sophia Genetics Sa Stock Forecast, Predictions & Price Target

Analyst price target for SOPH

Based on 1 analyst offering 12 month price targets for Sophia Genetics Sa

Min Forecast
$7.00+44.33%
Avg Forecast
$7.00+44.33%
Max Forecast
$7.00+44.33%

Should I buy or sell SOPH stock?

Based on 1 analyst offering ratings for Sophia Genetics Sa.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SOPH's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SOPH as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SOPH stock forecasts and price targets.

SOPH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-10Find Out Why

1 of 1

Forecast return on equity

Is SOPH forecast to generate an efficient return?

Company
N/A
Industry
20.41%
Market
228.52%

Forecast return on assets

Is SOPH forecast to generate an efficient return on assets?

Company
N/A
Industry
16.89%

SOPH earnings per share forecast

What is SOPH's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.13
Avg 2 year Forecast
-$0.89
Avg 3 year Forecast
-$0.70

SOPH revenue forecast

What is SOPH's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$77.1M+5.2%
Avg 2 year Forecast
$89.1M+21.63%
Avg 3 year Forecast
$106.0M+44.63%
SOPH's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SOPH revenue growth forecast

How is SOPH forecast to perform vs Health Information Services companies and vs the US market?

Company
12.76%
Industry
9.71%
Market
25.67%
SOPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SOPH's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SOPH vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
SOPH$4.85$7.00+44.33%Strong Buy
TBRG$23.02N/AN/A
SY$3.12$5.50+76.28%Strong Buy
DH$2.48$5.00+101.61%Buy
CARL$13.26$20.25+52.71%Strong Buy

Sophia Genetics Sa Stock Forecast FAQ

Is Sophia Genetics Sa Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SOPH) stock is to Strong Buy SOPH stock.

Out of 1 analyst, 1 (100%) are recommending SOPH as a Strong Buy, 0 (0%) are recommending SOPH as a Buy, 0 (0%) are recommending SOPH as a Hold, 0 (0%) are recommending SOPH as a Sell, and 0 (0%) are recommending SOPH as a Strong Sell.

If you're new to stock investing, here's how to buy Sophia Genetics Sa stock.

What is SOPH's earnings growth forecast for 2025-2027?

(NASDAQ: SOPH) Sophia Genetics Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 31.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Sophia Genetics Sa's earnings in 2025 is -$74,978,000.On average, 6 Wall Street analysts forecast SOPH's earnings for 2025 to be -$76,585,759, with the lowest SOPH earnings forecast at -$77,793,437, and the highest SOPH earnings forecast at -$74,088,987. On average, 6 Wall Street analysts forecast SOPH's earnings for 2026 to be -$60,668,839, with the lowest SOPH earnings forecast at -$59,841,105, and the highest SOPH earnings forecast at -$60,553,499.

In 2027, SOPH is forecast to generate -$47,520,079 in earnings, with the lowest earnings forecast at -$47,872,884 and the highest earnings forecast at -$46,305,617.

What is SOPH's revenue growth forecast for 2025-2027?

(NASDAQ: SOPH) Sophia Genetics Sa's forecast annual revenue growth rate of 12.76% is forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Sophia Genetics Sa's revenue in 2025 is $73,297,000.On average, 6 Wall Street analysts forecast SOPH's revenue for 2025 to be $5,231,822,336, with the lowest SOPH revenue forecast at $4,926,917,658, and the highest SOPH revenue forecast at $5,471,186,757. On average, 6 Wall Street analysts forecast SOPH's revenue for 2026 to be $6,048,429,527, with the lowest SOPH revenue forecast at $5,718,150,048, and the highest SOPH revenue forecast at $6,354,555,452.

In 2027, SOPH is forecast to generate $7,192,466,619 in revenue, with the lowest revenue forecast at $6,715,501,801 and the highest revenue forecast at $7,615,832,261.

What is SOPH's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SOPH) forecast ROA is N/A, which is lower than the forecast US Health Information Services industry average of 16.89%.

What is SOPH's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SOPH price target, the average SOPH price target is $7.00, with the highest SOPH stock price forecast at $7.00 and the lowest SOPH stock price forecast at $7.00.

The Wall Street analyst predicted that Sophia Genetics Sa's share price could reach $7.00 by Nov 10, 2026. The average Sophia Genetics Sa stock price prediction forecasts a potential upside of 44.33% from the current SOPH share price of $4.85.

What is SOPH's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SOPH) Sophia Genetics Sa's current Earnings Per Share (EPS) is -$1.12. On average, analysts forecast that SOPH's EPS will be -$1.13 for 2025, with the lowest EPS forecast at -$1.15, and the highest EPS forecast at -$1.09. On average, analysts forecast that SOPH's EPS will be -$0.89 for 2026, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.89. In 2027, SOPH's EPS is forecast to hit -$0.70 (min: -$0.71, max: -$0.68).

What is SOPH's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SOPH) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.